RNASET2 and ovarian cancer: In keeping with the above-mentioned data, by comparing gene expression in carboplatin-resistant (A2780-CBP) and cisplatin-resistant (A2780-DDP) ovarian cancer cells and their drug-sensitive counterparts (A2780), Yin et al. found that RNASET2 expression was significantly decreased in drug-resistant cells [57], thus suggesting a role for RNASET2 in drug resistance.